AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Our latest available data shows that ANAB has returned about 26.89% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 0.21% on average.

AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company, focusing on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology.

Here are some of the largest recent moves: FAIRMOUNT FUNDS MANAGEMENT LLC added 1,816,466 shares (+inf%) to their portfolio in Q4 2024, for an estimated $24,050,009 CAMBER CAPITAL MANAGEMENT LP ...

AnaptysBio (ANAB) stock gains as H.C. Wainwright upgrades the stock on promising Phase 2b trial data for its rheumatoid arthritis therapy rosnilimab. Read more here.

AnaptysBio (ANAB) stock dips as rival J&J's (JNJ) trial data for its anti-inflammatory agent similar to ANAB's lead asset disappoints in ulcerative colitis. Read more here.